FMOC-(R)-3-氨基-4-(4-硝基苯基)-丁酸 | 269398-78-9

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - FMOC-氨基酸
• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 中文名称: FMOC-(R)-3-氨基-4-(4-硝基苯基)-丁酸
• 中文别名: Fmoc-(r)-3-氨基-4-(4-硝基苯基)丁酸；(R)-N-芴甲氧羰基-3-氨基-4-(4-硝基苯基)丁酸；Fmoc-(R)-3-氨基-4-(4-硝基苯基)丁酸
• 英文名称: (R)-3-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-4-(4-nitrophenyl)butanoic acid
• 英文别名: (3R)-3-(9H-fluoren-9-ylmethoxycarbonylamino)-4-(4-nitrophenyl)butanoic acid
• CAS: 269398-78-9
• 化学式: C25H22N2O6
• mdl: MFCD01860920
• 分子量: 446.5
• InChiKey: HBORLQMDGYDDBJ-QGZVFWFLSA-N

物化性质

• 沸点：
  703.4±60.0 °C(Predicted)
• 密度：
  1.345±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  33
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  121
• 氢给体数：
  2
• 氢受体数：
  6

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  N
• 安全说明：
  S61
• 危险类别码：
  R50
• 包装等级：
  III
• 危险类别：
  9
• 危险性防范说明：
  P264,P270,P273,P280,P301+P312+P330,P302+P352+P312,P305+P351+P338+P310,P332+P313,P391,P501
• 危险品运输编号：
  3077
• 危险性描述：
  H302+H312,H315,H318,H411

文献信息

• Compositions for therapeutics, targeted PET imaging and methods of their use
  申请人：Memorial Sloan Kettering Cancer Center

  公开号：US10821195B2

  公开（公告）日：2020-11-03

  Described herein is a chelator for radiolabels (e.g., 89Zr) for targeted PET imaging that is an alternative to DFO. In certain embodiments, the chelator for 89Zr is the ligand, 3,4,3-(LI-1,2-HOPO) (“HOPO”), which exhibits equal or superior stability compared to DFO in chemical and biological assays across a period of several days in vivo. As shown in FIG. 1, the HOPO is an octadentate chelator that stabilizes chelation of radiolabels (e.g., 89Zr). A bifunctional ligand comprising p-SCN-Bn-HOPO is shown in FIG. 4 and FIG. 5. Such a bifunctional ligand can eliminate (e.g., 89Zr) loss from the chelate in vivo and reduce uptake in bone and non-target tissue. Therefore, the bifunctional HOPO ligand can facilitate safer and improved PET imaging with radiolabeled antibodies.

  本文描述了一种用于靶向 PET 成像的放射性标记（如 89Zr）的螯合剂，它是 DFO 的替代品。在某些实施方案中，89Zr 的螯合剂是配体 3,4,3-(LI-1,2-HOPO)（"HOPO"），与 DFO 相比，它在体内数天的化学和生物试验中表现出相同或更高的稳定性。如图 1 所示，HOPO 是一种八齿螯合剂，可稳定放射性标记（如 89Zr）的螯合。由 p-SCN-Bn-HOPO 组成的双功能配体如图 4 和图 5 所示。这种双功能配体可以消除螯合物在体内的（如 89Zr）损失，并减少骨骼和非目标组织的吸收。因此，双功能 HOPO 配体可促进放射性标记抗体更安全、更完善的 PET 成像。
• COMPOSITIONS FOR THERAPEUTICS, TARGETED PET IMAGING AND METHODS OF THEIR USE
  申请人：Memorial Sloan Kettering Cancer Center

  公开号：US20190298864A1

  公开（公告）日：2019-10-03

  Described herein is a chelator for radiolabels (e.g., 89 Zr) for targeted PET imaging that is an alternative to DFO. In certain embodiments, the chelator for 89 Zr is the ligand, 3,4,3-(LI-1,2-HOPO) (“HOPO”), which exhibits equal or superior stability compared to DFO in chemical and biological assays across a period of several days in vivo. As shown in FIG. 1 , the HOPO is an octadentate chelator that stabilizes chelation of radiolabels (e.g., 89 Zr). A bifunctional ligand comprising p-SCN-Bn-HOPO is shown in FIG. 4 and FIG. 5 . Such a bifunctional ligand can eliminate (e.g., 89 Zr) loss from the chelate in vivo and reduce uptake in bone and non-target tissue. Therefore, the bifunctional HOPO ligand can facilitate safer and improved PET imaging with radiolabeled antibodies.
• [EN] COMPOSITIONS FOR THERAPEUTICS, TARGETED PET IMAGING AND METHODS OF THEIR USE<br/>[FR] COMPOSITIONS POUR AGENTS THÉRAPEUTIQUES, IMAGERIE TEP CIBLÉE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：MEMORIAL SLOAN KETTERING CANCER CENTER

  公开号：WO2017105565A2

  公开（公告）日：2017-06-22

  Described herein is a chelator for radiolabels (e.g., 89Zr) for targeted PET imaging that is an alternative to DFO. In certain embodiments, the chelator for 89Zr is the ligand, 3,4,3-(LI-1,2- HOPO) ("HOPO"), which exhibits equal or superior stability compared to DFO in chemical and biological assays across a period of several days in vivo. As shown in FIG. 1, the HOPO is an octadentate chelator that stabilizes chelation of radiolabels (e.g., 89Zr). A bifunctional ligand comprising p-SCN-Bn-HOPO is shown in FIG. 4 and FIG. 5. Such a bifunctional ligand can eliminate (e.g., 89Zr) loss from the chelate in vivo and reduce uptake in bone and non-target tissue. Therefore, the bifunctional HOPO ligand can facilitate safer and improved PET imaging with radiolabeled antibodies.